HC Wainwright Forecasts Armata Pharmaceuticals Q1 Earnings

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Armata Pharmaceuticals in a report released on Friday, March 21st. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.50) EPS and Q4 2025 earnings at ($0.67) EPS.

Armata Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:ARMP opened at $1.79 on Monday. Armata Pharmaceuticals has a 1 year low of $1.79 and a 1 year high of $4.25. The stock has a market capitalization of $64.76 million, a PE ratio of -1.09 and a beta of 0.87.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.